Translational Research
From the Journals
Where women’s voices still get heard less
Only about one-third of board review lectures are presented by women oncologists, and early-career disparities also persist.
Feature
100 coauthored papers, 10 years: Cancer transplant pioneers model 'team science'
MSKCC medical oncologists share expertise in HSCT, Spanish background, a gift for mentoring, and 100 peer-reviewed publications written together...
Conference Coverage
Will TP53-mutated AML respond to immunotherapy?
NATIONAL HARBOR, MD. – Patients with TP53-mutated AML were shown to have increased immune infiltration, but it isn’t clear if they will respond...
From the Journals
TP53 double hit predicts aggressive myeloma
Researchers said the findings point to the usefulness of clonal competition assays to reveal the impact of genomic lesions in tumors and better...
From the Journals
BET inhibitors may target oncogene in ABC-like DLBCL
Preclinical research suggests TCF4 is an oncogene in ABC-like DLBCL and can be targeted via BET inhibition.
Feature
Preprints come to medicine: medRxiv launches with safeguards
The new repository of preprints in medicine is intended for researcher-to-researcher communication before publication in peer-reviewed journals....
From the Journals
Inhibitor may overcome ibrutinib resistance in MCL
The inhibitor, IACS-010759, decreased tumor growth and prolonged survival in mouse models of ibrutinib-resistant lymphoma.
From the Journals
Gene expression signature reveals high-grade GCB DLBCL
Patients with this signature had inferior survival outcomes.
Conference Coverage
Anti-GM-CSF antibody reduced CAR T-cell toxicity
HOUSTON – An early study shows the potential of lenzilumab to reduce CAR T-cell toxicity.
From the Journals
Chemo-resistant reserve HSCs maintained in bone marrow
These findings could open new avenues for treating blood diseases and autoimmune disorders.
Commentary
NIH director expresses concern over CRISPR-cas9 baby claim
“Lest there be any doubt, and as we have stated previously, NIH does not support the use of gene-editing technologies in human embryos.”